Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ -years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: www.kyowakirin.com


Helsinn is a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, thanks to a consolidated track record, solid revenue stream in B2B and strong cash flow and cash position.

Helsinn is building market differentiation in B2C in the U.S. and China and is owned by a third-generation healthcare entrepreneurial family.

Since 1976, Helsinn has been improving the lives of patients, guided by core family values of respect, integrity and quality.

2014 LogoHelsinn_edited.png

Innate Pharma is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes through therapeutic antibodies that harness the immune system to fight cancer. Our broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate’s key proprietary asset is lacutamab, a first-in-class anti-KIR3DL2 antibody, which is currently being investigated in mycosis fungoides, Sézary syndrome as well as in peripheral T-cell lymphoma.  

For more information on lacutamab, including the ongoing, multi-cohort Phase 2 clinical trial, TELLOMAK, currently recruiting patients with Sézary syndrome and mycosis fungoides, please visit www.innate-pharma.com/products/lacutamab.

INNATEhornoir Logo.png

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Our Specialty Brands segment includes branded medicines and the Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.  

Therakos is a specialty brand of Mallinckrodt that focuses on the delivery of ECP Immunomodulation. The THERAKOSTM CELLEX™ Photopheresis System is the world’s only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide. 

Beyond the THERAKOS™ CELLEX™ Photopheresis System, we offer a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver optimised ECP immunomodulation to patients.  Therakos have been crafting ECP solutions (products, services and education) since 1987. 

JPEG TKS_ECP_Immunomodulation TM Logo_edited.png

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a tight connection from research to development to commercialization and meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.

We complement our deep in-house expertise with symbiotic partnerships to unlock promising science wherever it emerges. 

For more information: www.takedaoncology.com.

Takeda_Logo_16 by 9_edited.png



fk logo.png

The single focus of Fresenius Kabi TCT EMEA is to enable our Transfusion Medicine and Cell Therapies (TCT) customers to achieve their mission in the 100+ countries of the region. We are global leaders in apheresis technology for both blood component collection and extracorporeal therapies, bringing new innovations focusing on donor and patient comfort. Besides our broad portfolio, our strength has always been our people. Our expert team is dedicated to forming deep partnerships with our customers, listening to their needs and responding with innovative thinking, collaboration and a shared commitment to the donors and patients we both serve. To learn more, visit our website amicusblue-fresenius-kabi.com or contact us at tct.emea@fresenius-kabi.com.


4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany.



VJHemOnc logo.png

VJHemOnc is an independent, open-access video journal that provides trusted and up-to-date information in hematological oncology for HCPs through innovative digital media – including video interviews, panel discussions, podcasts, editorial features and e-learning courses.We rapidly disseminate the latest news from global medical congresses to keep the HCP community informed.For our latest coverage of conferences including the EORTC Cutaneous Lymphoma Meeting, sign up to our newsletter here: VJHemOnc.com/newsletter